<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="1899">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on December 16, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05136443</url>
  </required_header>
  <id_info>
    <org_study_id>2021-002</org_study_id>
    <nct_id>NCT05136443</nct_id>
  </id_info>
  <brief_title>Loteprednol Etabonate 0.25% for Prevention of Cornea Transplant Rejection</brief_title>
  <official_title>Prospective Analysis of Loteprednol Etabonate Ophthalmic Suspension 0.25% for Prevention of Immunologic Rejection After Descemet Membrane Endothelial Keratoplasty</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Price Vision Group</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Kala Pharmaceuticals, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Price Vision Group</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess off-label use of loteprednol etabonate 0.25%&#xD;
      ophthalmic suspension (Eysuvis) for prevention of immunologic rejection in the first year&#xD;
      after Descemet membrane endothelial keratoplasty (DMEK). Topical corticosteroids have long&#xD;
      been the mainstay for preventing and treating cornea transplant rejection although none are&#xD;
      specifically approved for this purpose. The rates of immunologic rejection episodes and&#xD;
      steroid-induced ocular hypertension will be compared with the respective rates observed in&#xD;
      earlier studies with prednisolone acetate 1% suspension, loteprednol etabonate 0.5% gel, and&#xD;
      fluorometholone 0.1% suspension after DMEK.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 23, 2021</start_date>
  <completion_date type="Anticipated">February 2023</completion_date>
  <primary_completion_date type="Anticipated">January 2023</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Immunologic rejection</measure>
    <time_frame>11 months</time_frame>
    <description>incidence of immunologic rejection episodes</description>
  </primary_outcome>
  <primary_outcome>
    <measure>steroid-induced ocular hypertension</measure>
    <time_frame>11 months</time_frame>
    <description>incidence of steroid-induced ocular hypertension</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">116</enrollment>
  <condition>Corneal Endothelial Dystrophy</condition>
  <condition>Corneal Edema</condition>
  <arm_group>
    <arm_group_label>Preventative Treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Loteprednol etabonate ophthalmic suspension 0.25% dosed 4 times daily for 2 months, 3 times daily for one month, twice daily for one month, and once daily until the 1 year postop exam.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>loteprednol etabonate 0.25% ophthalmic suspension</intervention_name>
    <description>tapering dose</description>
    <arm_group_label>Preventative Treatment</arm_group_label>
    <other_name>Eysuvis</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  o At least 18 years of age&#xD;
&#xD;
               -  Male or female patient who had DMEK within the past 1 to 7 weeks.&#xD;
&#xD;
               -  Patient is able and willing to administer eye drops.&#xD;
&#xD;
               -  Patient is able to comprehend and has signed the Informed Consent form.&#xD;
&#xD;
               -  Patient is likely to complete the 11-month study duration.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  o A history of a previous rejection episode in the study eye&#xD;
&#xD;
               -  A patient exhibiting intraocular inflammation.&#xD;
&#xD;
               -  A patient with a known sensitivity to any of the ingredients in the study&#xD;
                  medications&#xD;
&#xD;
               -  A patient who has a condition (i.e., UNCONTROLLED systemic disease) or is in a&#xD;
                  situation which in the investigator's opinion may put the patient at significant&#xD;
                  risk, may confound the study results, or may interfere significantly with the&#xD;
                  patient's participation in the study&#xD;
&#xD;
               -  A patient with abnormal eyelid function.&#xD;
&#xD;
               -  A patient that is exhibiting active corneal ulceration, keratitis, or&#xD;
                  conjunctivitis, or who has a history of herpetic keratitis.&#xD;
&#xD;
               -  Presence of any ocular disease that would interfere with the evaluation of the&#xD;
                  study treatment. However, patients with a history of cystoid macular edema,&#xD;
                  age-related macular degeneration, controlled glaucoma, corneal&#xD;
                  neovascularization, and other non-interfering comorbidities may be enrolled.&#xD;
&#xD;
               -  A patient with a history of non-compliance with using prescribed medication.&#xD;
&#xD;
               -  Patients who are pregnant or planning to become pregnant within the duration of&#xD;
                  the study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Francis W Price, Jr., MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Price Vision Group</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Marianne O Price, PhD</last_name>
    <phone>317-814-2990</phone>
    <email>mprice@cornea.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>Price Vision Group</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46260</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marianne Price, Ph.D</last_name>
      <phone>317-814-2990</phone>
      <email>mprice@cornea.org</email>
    </contact>
    <investigator>
      <last_name>Francis W Price, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Price MO, Feng MT, Scanameo A, Price FW Jr. Loteprednol Etabonate 0.5% Gel Vs. Prednisolone Acetate 1% Solution After Descemet Membrane Endothelial Keratoplasty: Prospective Randomized Trial. Cornea. 2015 Aug;34(8):853-8. doi: 10.1097/ICO.0000000000000475.</citation>
    <PMID>26020827</PMID>
  </reference>
  <reference>
    <citation>Price MO, Price FW Jr, Kruse FE, Bachmann BO, Tourtas T. Randomized comparison of topical prednisolone acetate 1% versus fluorometholone 0.1% in the first year after descemet membrane endothelial keratoplasty. Cornea. 2014 Sep;33(9):880-6. doi: 10.1097/ICO.0000000000000206.</citation>
    <PMID>25062336</PMID>
  </reference>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>October 29, 2021</study_first_submitted>
  <study_first_submitted_qc>November 17, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">November 29, 2021</study_first_posted>
  <last_update_submitted>November 29, 2021</last_update_submitted>
  <last_update_submitted_qc>November 29, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">December 13, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Corneal Edema</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Loteprednol Etabonate</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

